<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97578">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02074657</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005146-38</org_study_id>
    <nct_id>NCT02074657</nct_id>
  </id_info>
  <brief_title>&quot;LANK-2&quot;: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia</brief_title>
  <acronym>LYDIA</acronym>
  <official_title>&quot;LANK-2&quot;: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine safety profile of immunotherapy with natural killer cells and activated
      expanded (NKAEs) after salvage chemotherapy in children, adolescents and young adults with
      relapsed or refractary acute leukemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the safety of activated and expanded NK cell (NKAE) immunotherapy after salvage chemotherapy in patients with relapsed or refractary acute leukemia</measure>
    <time_frame>2 months after infusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse events according to NCI-CTCAE v4.0 CRITERIA as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections</measure>
    <time_frame>End of infusion and follow-up (2 months and 1 year)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hematological recovery (neutrophils &gt;500/microL, lymphocytes &gt;250/microL and platelets &gt;50.000/microL), days of hospitalization, in each cycle Immune</measure>
    <time_frame>End of infusion and follow-up (2 months and 1 year)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate according to cytomorphic and by &quot;minimal residual disease&quot; criteria (cytometry and/or real time PCR) at the end of the treatment</measure>
    <time_frame>End of infusion and follow-up (2 months and 1 year)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution: Median of T-cell , B, NK, Natural Killer T cell (NKT) and dendritic cells count and subpopulations of T and NK lymphocytes (cel/microL) during posttreatment follow-up period.</measure>
    <time_frame>End of infusion and follow-up (2 months and 1 year)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Relapsed/Refractory Paediatric Acute Leukaemia</condition>
  <arm_group>
    <arm_group_label>Activated natural killer cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Activated and expanded natural killer cells (NKAEs)</intervention_name>
    <description>Activated and expanded natural killer cells (NKAEs) from haploidentical donor</description>
    <arm_group_label>Activated natural killer cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients between 0 and 23 years of age with diagnosis of acute lymphoblastic
             leukemia, in second relapse situation, posttransplant relapse or refractary, or

          2. Patients between 0 and 23 years of age with diagnosis of acute myeloblastic leukemia,
             relapsed or refractary. (Patient must meet inclusion criteria 1 or 2)

          3. Lansky index &gt; 60%

          4. Mild (&lt;2) functional organs alteration (hepatic, renal, respiratory) according to
             National Cancer Institute criteria (NCI CTCAE v4).

          5. Left ventricular ejection fraction &gt; 39%

          6. To grant informed consent in accordance with the current legal regulations.

          7. Presence of a compatible haploidentical donor (father or mother or brother).

        Exclusion Criteria:

          1. Patients with history of bad therapeutical compliance

          2. Patients not valid after psycho-social evaluation

          3. Positive HIV serology
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pérez-Martínez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Infantil Universitario La Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Pérez-Martínez, MD, PhD</last_name>
    <phone>+34917277223</phone>
    <email>aperezmartinez@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Infantil Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Pérez Martínez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquín Martínez-López, MD</last_name>
      <phone>+34917792787</phone>
      <email>jmartinezlo@hematologia12octubre.com</email>
    </contact>
    <investigator>
      <last_name>Joaquín Martínez-López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Antonio Pérez Martínez</investigator_full_name>
    <investigator_title>MD, Servicio de Hemato-Oncología Pediátrica</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>NKAEs</keyword>
  <keyword>Expanded haploidentical natural killer cells</keyword>
  <keyword>Activated natural killer cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
